On September 12, 1985, a surgeon in the small German town of Böblingen removed a gallbladder through a few tiny incisions and a scope he had partly built himself. Erich Mühe called his instrument the Galloscope. His colleagues called what he was doing “Mickey Mouse surgery.” When one of his patients later died, he was charged with manslaughter. The German Surgical Society dismissed his technique; he presented it and was, more or less, laughed out of the room.
Within a decade, the thing they had laughed at was the standard of care for one of the most common operations on earth. By the early 1990s, general surgeons were flocking to weekend courses to learn it, and the discipline we now call minimally invasive surgery — laparoscopic everything, robotic everything, the whole architecture of the modern operating theater — had been reorganized around Mühe’s basic insight. He was recognized as first, at last, in 1999.
Here is the part worth sitting with. Mühe did not invent a new operation. Gallbladders had been removed for a century. He invented a new way in — and the new way in turned out to matter more than any single procedure it enabled, because it did not just improve gallbladder surgery. It made a category of surgery possible that no one had fully scoped in advance.
This is the pattern I want to argue for, because it is the pattern our whole company is built on: in medicine, and especially in the gut, the unit of real progress is not the instrument and not the molecule. It is the route. And a new route is never just a procedure. It is a platform.
What PEG actually built
Our field has its own version of the Mühe story, and it is the one this series keeps returning to. In 1979, two surgeons in Cleveland threaded a feeding tube through the wall of the stomach with the help of an endoscope — on a four-and-a-half-month-old infant — and skipped the laparotomy entirely. Before percutaneous endoscopic gastrostomy, PEG, putting a durable tube into the stomach meant open abdominal surgery. After it, the same result took less than fifteen minutes under sedation.
If you measured PEG as a device, you would say: a better gastrostomy. That measurement misses almost everything that happened next. Because the moment you could place long-term enteral access without a surgeon and an operating theater, you could place a great deal more of it — and reach people who had never been reachable. A niche procedure at the end of the 1980s, PEG had grown to more than two hundred thousand placements a year by the turn of the century. But the number is the least of it. What PEG actually built was a set of things that did not exist before there was an easy way in:
Home enteral nutrition — an entire model of care in which people who cannot eat live at home instead of in a hospital, on their own schedule, for years. Interventional and endoscopic nutrition as a practice. The low-profile “button,” the radiologically placed variants, a whole ecosystem of connectors and pumps and formulas. A patient population — neurologic, oncologic, pediatric — that could be fed durably and sent home.
None of that was the tube. All of it was the route. PEG is the last genuinely new way into the gut that medicine adopted, and the field it created is still the field we live in, forty-seven years later.
The pattern under the anecdotes
Step back from the two stories and the shape is the same. A therapeutic agent — a drug, a formula — acts within the access you already have. It works through the existing plumbing. A route changes the plumbing itself, and changing the plumbing is generative in a way that acting within it is not, because it hands other people a new place to stand.
PEG’s inventors did not design home enteral nutrition. Mühe did not design robotic surgery. They designed a way in, and the way in did the rest. It is worth naming the obvious counterexample, because it sharpens the point. The GLP-1 era — the most consequential thing to happen to metabolic medicine in a generation — is a molecule story, and a spectacular one. But it operates through an access route we have had for a hundred years: the needle. The innovation is what travels through the route, not the route itself. That is not a criticism; it is a distinction. Molecules and routes are different kinds of leverage — and the routes, quietly, had run out.
Which brings us to the jejunum
For three and a half thousand years — the lineage of enteral feeding really does run back to Egyptian medical papyri — the story of getting nutrition into a human being has been, overwhelmingly, a story about reaching the stomach. Down the nose, through the mouth, through the abdominal wall: nearly every route medicine has adopted terminates, by default, in the stomach. The small bowel — the jejunum, a foot or so past the stomach’s exit — has been reachable, but never routinely, never repeatably, never without either a surgeon’s incision or an endoscopist’s suite. There has never been an ordinary way in.
That absence is the whole opportunity, and it is what Alsteni exists to close. Our device establishes a route to the jejunum — and to the stomach — anchored intraorally, placed without surgery and without endoscopy. Our first-in-human trial, published in Nature’s Nutrition & Diabetes in 2020, showed the approach was well tolerated and produced a within-group weight-loss signal of −2.40 kg over 14 days (p = 0.008). We completed FDA Pre-Submission Q252869 in December 2025; our first indication follows a Class II 510(k) regulatory pathway. The core device patent issued in April 2026, with protection through May 2045.
By the reckoning this series has been building toward, that makes it the sixth access route to the human gut — and the first new one since PEG in 1979. Like every new route before it, it enters through the least glamorous door: standard enteral nutrition, feeding people who need to be fed, making the front end of tube feeding reliable in a way it has stubbornly never been. That is the beachhead. It is also, historically, exactly where platforms begin.
What a jejunal interface makes buildable
Here is where I have to be disciplined, because this is the part that is easy to oversell — and I would rather undersell it precisely.
The jejunum is not only a place to deliver calories. It is a signaling surface. It is lined with the L-cells that, in response to nutrients arriving in the lumen, release the body’s own satiety hormones — GLP-1, which the incretin drugs were built to imitate, and PYY. That physiology has been understood for years. What has been missing is not the biology. What has been missing is a route: a reliable, repeatable, non-surgical way to reach the surface and act on it, so the biology becomes something you can engineer around instead of merely observe.
Give the field that route, and a research frontier opens that used to sit behind a laparotomy. The premise is inverted from the drug era: not administering the molecule from outside, but occasioning the patient’s own L-cells to release it — elevating endogenous satiety signaling through the placement and timing of nutrients rather than through an injection. Beyond our first indication, that is the direction our own metabolic work points. But the more important claim is the platform claim, and it is at once more modest and more interesting than any single indication: a jejunal interface is a place other people can now build things we have not thought of. Metabolic research that needed surgical access. Delivery strategies that needed the small bowel and never had a practical door to it. And, unglamorously, a solved front end for the enormous population that already depends on enteral nutrition and is failed by the tubes we have.
We can name where we think it leads. We cannot name everything it will hold — and if we could, it would not be a platform.
The oldest constraint
Return, one last time, to the through-line of these histories. For as long as medicine has tried to feed the body it could not feed by mouth, the failures have rarely been failures of ambition or of ingredients. The nasogastric tube’s inventors were ingenious across two centuries; what defeated them was the route — a passage the body was never built to tolerate, still the most painful ordinary procedure we perform. The surgeons who first cut a path to the stomach were not short on skill; early on, they were defeated by the route, and patients died for it. PEG did not win because it was a cleverer tube. It won because it was a better way in.
The constraint on feeding the human body, across three and a half thousand years, was never the food and never the will. It was always the door. Build a new one, and — if the history means anything — the field follows.
A platform does not announce everything it will hold. It changes what is possible to build, and then it waits for the builders. We are building the route. The field is the point.
— Nicholas G. Demetriades